Delving into the Latest Updates on Chiesi SAS with Synapse

Overview

Basic Info

Introduction

Chiesi SAS is a company that specializes in the wholesale and distribution of pharmaceutical products. Established in 1992, the company is based in Bois-Colombes, France.

Tags

Respiratory Diseases

Other Diseases

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Top 5 Drug Type	Count

Biological products	1

This is an observational, prospective, multicentric, cohort study conducted in France to evaluate the QoL in COPD patients treated with TRIMBOW NEXThaler 88/5/9 in a routine clinical practice setting. Patients enrolled in this study will be patients diagnosed with a COPD with a ratio of post-bronchodilator (salbutamol 400 μg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7 to whom TRIMBOW NEXThaler 88/5/9 has been initiated by an hospital or local pulmonologists in accordance with clinical practice and marketing authorization.

Start Date01 Aug 2023

Sponsor / Collaborator

Chiesi SAS

[+1]

NCT05728749 / RecruitingNot Applicable

A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes

TriMaximize, a non-interventional trial aims to collect prospective, longitudinal data from asthma patients under routine care, for whom their treating physician has decided to prescribe Trimbow® (beclometasone/formoterol/glycopyrronium).

Start Date03 Mar 2023

Sponsor / Collaborator

Chiesi SAS

[+1]

CTR20180475 / CompletedPhase 3

比较丙酸倍氯米松/富马酸福莫特与布地奈德/富马酸福莫特罗治疗COPD的24周临床试验

[Translation] A 24-week clinical trial comparing beclomethasone dipropionate/formoterol fumarate with budesonide/formoterol fumarate in the treatment of COPD

主要目的：证明CHF1535pMDI治疗COPD患者在肺功能方面（第24周的早晨用药前一秒用力呼气量（FEV1）较基线变化）非劣效于信必可都保。次要目的：评估CHF1535pMDI对其它肺功能参数和患者报告的结局（PRO）的影响。评估研究治疗的安全性和耐受性。

[Translation]

Primary objective: To demonstrate the non-inferiority of CHF1535pMDI to Symbicort in lung function (change from baseline in forced expiratory volume in one second (FEV1) before morning dosing at week 24) in patients with COPD. Secondary objectives: To assess the effect of CHF1535pMDI on other lung function parameters and patient-reported outcomes (PROs). To assess the safety and tolerability of the study treatment.

Start Date30 Jul 2018

Sponsor / Collaborator

Chiesi SAS

[+1]

100 Clinical Results associated with Chiesi SAS

Login to view more data

0 Patents (Medical) associated with Chiesi SAS

Login to view more data

100 Deals associated with Chiesi SAS

Login to view more data

100 Translational Medicine associated with Chiesi SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Poractant Alfa	Respiratory Distress Syndrome, Newborn More	Approved
Tanimilast ( M3 receptor x PDE4 )	Asthma More	Pending
CHF-6523 ( PI3K family )	Asthma More	Pending
CHF-6333 ( ELA2 )	Asthma More	Pending
Efdoralprin alfa ( A1AT )	Asthma More	Pending